All you need to read in the other general journalsBMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e3731 (Published 29 May 2012) Cite this as: BMJ 2012;344:e3731
Thrombolysis for older adults with acute ischaemic stroke
Two new analyses suggest the benefits of thrombolysis for acute stroke extend to adults aged >80 years. A large trial and an updated meta-analysis also show that intravenous recombinant tissue plasminogen activator (rt-PA) can work beyond the recommended three hour window between symptoms and treatment, although the precise time limits for treatment aren’t yet clear.
The new trial included 3035 adults with acute ischaemic stroke, who were treated up to six hours after symptom onset. More than half were over 80 years old. While results were mixed, rt-PA did seem to reduce the level of disability over six months in secondary analyses (a significant shift in Oxford handicap scores, adjusted odds ratio 1.27 (95% CI 1.10 to 1.47)).
When the new data were pooled with data from nine previous trials, adults treated with rt-PA were significantly more likely to be alive and independent at the end of follow-up than controls given placebo or usual care (1611/3483 (46.3%) v 1434/3404 (42.1%), odds ratio 1.17 (1.06 to 1.29))⇑. The benefits looked similar for people older and younger than 80 years. As did the risks: rt-PA was associated with a significant excess of intracranial bleeds (7.7% v 1.8%, odds ratio 3.72 (2.98 to 4.64)) and early deaths (8.9% v 6.4%, 1.44 (1.18 to 1.76)). But later benefits outstripped the early hazard and, by the end of follow-up, adults of all ages did better after rt-PA.
As expected, rt-PA worked best when given within three hours of stroke onset, and timing remains critical, says a linked editorial (doi:10.1016/S0140-6736(12)60822-8).
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial